CSL to Bring 1st Hemophilia B Gene Therapy to Japan Too; Eyes Riveted on Price Tag

CSL Behring Japan President Jean-Marc Morange Last month, CSL Behring won US FDA approval for Hemgenix (etranacogene dezaparvovec) as the first gene therapy for hemophilia B, making the headlines with its US$3.5 million list price. The company’s Japan chief Jean-Marc...read more